Novel CTC Culture Method Developed to Study Metastatic Cancer

During metastasis, cells that escape the primary tumor into the circulatory system are known as circulating tumor cells (CTCs).

Circulating tumor cells represent a unique population of cells that can be used to investigate the mechanistic underpinnings of metastasis. Unfortunately, current technologies designed for the isolation and capture of CTCs are inefficient. Existing literature for in vitro CTC cultures report low (6% to 20%) success rates.

Scientists from Georgetown University Medical Center (Washington, DC, USA) enrolled from 12 metastatic breast cancer patients representing all three major subtypes, HER2 positive, hormone receptor positive, and triple negative and samples from five healthy donors. After collecting a patient's blood sample, the team removed red blood cells (RBCs) and granulocytes using gradient centrifugation. They then harvest the rest of the cells, including CTCs, and put them into a custom cell culture growth medium for culture, followed by downstream analysis.

To see whether they had indeed cultured CTCs, the group then tested for the presence of epithelial, mesenchymal, and breast tissue markers to establish the cells' tissue of origin using reverse-transcriptase quantitative polymerase chain reaction (qRT-PCR). They selected cytokeratin 5 and 8 and mammaglobin and successfully identified all three biomarkers in all 12 cultures. The team then used RNA-seq on the six samples that yielded sufficient RNA and could be cultured for more than 30 days in order to characterize their gene expression. These six samples all contained CD45+ leukocytes, they noted, which have previously been shown to support CTC survival.

Overall, the investigators identified 7,234 genes that were significantly differentially expressed in the CTCs-containing samples compared to the healthy donors. Increased expression of multiple genes was correlated with a significant drop in overall patient survival, they found. Using multiple bioinformatics tools to confirm that the CTCs in the samples originated from the cancers, the team identified 52 significantly enriched key cancer pathways and 21 enriched genes that are important to breast cancer progression and metastasis. The group mainly found enriched CD8 T cells, neutrophils, and macrophages in the CTC cultures and noted that the isolation technique appeared to favor the survival of macrophages and neutrophils.

Seema Agarwal, PhD, the senior author and associate professor of pathology, said, “We could take DNA and RNA from cultured CTCs and do a detailed genomic analysis that can be done very quickly in a more meaningful way, as prior to expansion, there are very few CTCs in the patient's blood. We don't know whether the cultured cells represent the heterogeneity of the CTCs, but as we move forward, we hope to characterize the heterogeneity of the cells.”

The authors concluded that once profiled, CTCs can provide a significant amount of information based solely on their identity as an intermediary stage of metastasis. Comparison of CTCs with primary tumors would enable the identification of metastatic drivers and lead to the development of metastasis-preventing therapies. Thus, having a standardized method for the capture and culture of CTCs is a pressing need. The study was published on September 28, 2020 in the journal Cancers.

Related Links:
Georgetown University Medical Center